Loading
Loading…
Loading…
| # | Schedule | Awarded To | Bids | Value |
|---|---|---|---|---|
| 1 | Schedule 1 | PHARMA (INDIA) | 6 | ₹18,900 |
| 2 | Schedule 2 | PHARMA (INDIA) | 7 | ₹36,180 |
| 3 | Schedule 3 | PHARMA (INDIA) | 3 | ₹45,360 |
| 4 | Schedule 4 | PHARMA (INDIA) | 5 | ₹24,360 |
| 5 | Schedule 5 | PHARMA (INDIA) | 4 | ₹27,720 |
Tender Value
Refer Docs
EMD Value
Exempted
Closing Date
26 Jun 2026, 4:00 pmClosed
OXCARBAZEPINE 150MG TAB
ROSUVASTATIN 20MG TAB
SOLIFENACIN 5MG TAB
PROPRANOLOL TR 40 MG TAB
PRUCALOPRIDE 2MG TAB
PYRIDOXINE 40MG TAB
QUITIAPINE 50 MG TAB
9447330
GEM/2026/B/7645608
Two Packet Bid
OXCARBAZEPINE 150MG TAB,ROSUVASTATIN 20MG TAB,SOLIFENACIN 5MG TAB,PROPRANOLOL TR 40 MG TAB,PRUCALOP
Mumbai, Maharashtra
Item wise evaluation
BOQ
7 documents required · 7 mandatory
2 yrs
₹1 L
₹1 L
20%
Exempted
Yes
26 Jun 2026
16 Jun 2026
26 Jun 2026
| Item No | Item Title | Qty | Unit | Consignee | Delivery (days) |
|---|---|---|---|---|---|
| 1 | OXCARBAZEPINE 150MG TAB | 12,600 | NO | Mumbai | 30 |
| 2 | ROSUVASTATIN 20MG TAB | 54,000 | NO | Mumbai | 30 |
| 3 | SOLIFENACIN 5MG TAB | 42,000 | NO | Mumbai | 30 |
| 4 | PROPRANOLOL TR 40 MG TAB | 42,000 | NO | Mumbai | 30 |
| 5 | PRUCALOPRIDE 2MG TAB | 9,000 | NO | Mumbai | 30 |
| 6 | PYRIDOXINE 40MG TAB | 4,800 | NO | Mumbai | 30 |
| 7 | QUITIAPINE 50 MG TAB | 30,000 | NO | Mumbai | 30 |
Tap a document below to read it instantly. You can also download everything as a ZIP if you prefer.
bid_9447330.pdf
GEM_BID • 0.14 MB
bbqr-8_2026-06-10-11-59-50_0a8b38a497eb3614f03580d59e2bcd72.pdf
BOQ • 0.57 MB
boq_item_sample_file-4_2026-06-10-11-59-50_2ea0a21103498769ad2da392a33c6881.csv
BOQ • 0.00 MB
gtc.pdf
GEM_OTHER • 0.71 MB
Download all tender documents and submit your bid
Disclaimer: TenderKart has made every reasonable effort to ensure that the information on this page is accurate and authentic, however it cannot be held liable for any third-party claims or losses or any damages. TenderKart makes no warranty, expressed or implied, as to the results obtained from the use of this information. If you notice any error or omission, please let us know at .